Congruence gets $32 million financing to advance genetic obesity candidate drug

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine

Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia

GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours

Akums gets approval for triple combination diabetes treatment

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Healthium launches Theruptor Novo for diabetic foot ulcers

Theruptor Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing

Enveda appoints Vanitha Sekar as Chief Business Officer

She joins Enveda from Gilead Sciences